Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: Long-term observations

Bone Marrow Transplantation

Volumn 51, Issue 3, 2016, Pages 398-402

  Snarski, E ^a   Milczarczyk, A ^b   Halaburda K ^a   Torosian, T ^a   Paluszewska, M ^a   Urbanowska, E ^a   Krol M ^a   Boguradzki, P ^a   Jedynasty, K ^b   Franek, E ^b,c   Wiktor Jedrzejczak, W ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Central Hospital   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HEMOGLOBIN A1C; THYMOCYTE ANTIBODY; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; DEATH; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOABLATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; NEUTROPENIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REMISSION; SEPSIS; TREATMENT INDICATION; YOUNG ADULT; ADOLESCENT; AUTOGRAFT; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; MORTALITY; MULTICENTER STUDY; TIME FACTOR; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; AUTOGRAFTS; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; REMISSION INDUCTION; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 84959565694     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.294     Document Type: Article

References (18)

1. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with azathioprine. Diabetes 1985; 34: 1306-1308.
2. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosupression with azatioprine and prednisone in recent-onset insulindependent diabetes mellitus. N Engl J Med 1988; 319: 599-604.
3. Cyclosporin-induced remission of IDDM after early intervention: association of 1yr of cyclosporin treatment with enhanced insulin secretion. Canadian-European Randomized Control Trial Group. Diabetes 1988; 37: 1574-1582.
4. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and ?-cell function: two-year results. Diabetes Care 2014; 37: 453-459.
5. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
6. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr et al. Protégé Trial Investigators Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial. Lancet 2011; 378: 487-497.
7. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al. Type 1 Diabetes TrialNet GAD Study Group Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378: 319-327.
8. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM et al. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant 2013; 19: 1126-1129.
9. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-1576.
10. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Król M et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type 1. Bone Marrow Transplant 2011; 46: 562-566.
11. Gu W, Hu J, Wang W, Li L, Tang W, Sun S et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care 2012; 35: 1413-1419.
12. Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves ?-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 1729-1736.
13. Zhang X, Ye L, Hu J, Tang W, Liu R, Yang M et al. Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient. PLoS ONE 2012; 7: e31887.
14. D'Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes 2014; 63: 3041-3046.
15. Snarski E, Szmur?o D, Ha?aburda K, Król M, Urbanowska E, Milczarczyk A et al. An economic analysis of autologous hematopoietic stem cell transplantation (HSCT) in the treatment of new onset type 1 diabetes. Acta Diabetol 2015 52: 881-888.
16. Melanson SE, Stevenson K, Kim H, Antin JH, Court MH, Ho VT et al. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol 2010; 85: 967-971.
17. Dave SD, Trivedi HL, Chooramani SG, Chandra T. Management of type 1 diabetes mellitus using in vitro autologous adipose tissue trans-differentiated insulinmaking cells. BMJ Case Rep 2013; 2013: pii: bcr2013200226.
18. Dahlquist G, Källén B. Mortality in childhood-onset type 1 diabetes: a populationbased study. Diabetes Care 2005; 28: 2384-2387.